First Trust Advisors LP Buys Shares of 22,164 Diplomat Pharmacy Inc (DPLO)

First Trust Advisors LP acquired a new position in shares of Diplomat Pharmacy Inc (NYSE:DPLO) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 22,164 shares of the company’s stock, valued at approximately $298,000.

Other large investors also recently modified their holdings of the company. Comerica Bank lifted its holdings in shares of Diplomat Pharmacy by 7.1% during the third quarter. Comerica Bank now owns 54,799 shares of the company’s stock valued at $1,144,000 after purchasing an additional 3,652 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Diplomat Pharmacy by 7.8% during the third quarter. Wells Fargo & Company MN now owns 95,621 shares of the company’s stock valued at $1,856,000 after acquiring an additional 6,898 shares in the last quarter. Prudential Financial Inc. increased its position in shares of Diplomat Pharmacy by 10.4% during the third quarter. Prudential Financial Inc. now owns 122,906 shares of the company’s stock valued at $2,386,000 after acquiring an additional 11,580 shares in the last quarter. Rhumbline Advisers increased its position in shares of Diplomat Pharmacy by 6.9% during the third quarter. Rhumbline Advisers now owns 132,535 shares of the company’s stock valued at $2,573,000 after acquiring an additional 8,606 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Diplomat Pharmacy by 32.4% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 13,500 shares of the company’s stock valued at $262,000 after acquiring an additional 3,307 shares in the last quarter. Institutional investors and hedge funds own 86.81% of the company’s stock.

NYSE:DPLO opened at $5.55 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.00 and a debt-to-equity ratio of 0.94. Diplomat Pharmacy Inc has a 12 month low of $4.99 and a 12 month high of $28.74. The company has a market capitalization of $411.93 million, a price-to-earnings ratio of 27.75 and a beta of 0.72.

Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Friday, March 15th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.10). Diplomat Pharmacy had a positive return on equity of 5.51% and a negative net margin of 5.50%. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.41 billion. During the same period last year, the firm posted $0.09 EPS. The company’s revenue for the quarter was up 17.8% on a year-over-year basis. On average, sell-side analysts forecast that Diplomat Pharmacy Inc will post 0.34 earnings per share for the current year.

Several brokerages recently weighed in on DPLO. William Blair downgraded shares of Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a research report on Monday, January 7th. Raymond James raised shares of Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and raised their price target for the company from $5.86 to $8.00 in a research report on Thursday, March 21st. They noted that the move was a valuation call. Credit Suisse Group reduced their price target on shares of Diplomat Pharmacy from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, April 2nd. ValuEngine downgraded shares of Diplomat Pharmacy from a “sell” rating to a “strong sell” rating in a research report on Monday, February 4th. Finally, Wells Fargo & Co reduced their price target on shares of Diplomat Pharmacy from $16.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, March 19th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.42.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/27/first-trust-advisors-lp-purchases-shares-of-22164-diplomat-pharmacy-inc-dplo.html.

Diplomat Pharmacy Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: Resistance Level

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.